CEO Mark Caffrey underscores the urgency of developing novel treatment modalities for mental health disorders: “Approximately 70 percent of patients taking pharmaceutical antidepressants do not achieve remission and up to 25 percent stop taking them due to severe side effects. Unfortunately, these numbers are not good enough. It is therefore crucial that we begin to develop entirely new ways to treat these disorders. This is why the discoveries of Dr. Venturino and Prof. Siegert are so exciting, as they open up the potential for a completely new treatment modality that is free of side effects and simple for patients to use.”
The Syntropic Medical device aims to provide a safe, effective, and user-friendly therapy option for patients who have not responded to conventional treatments. Syntropic Medical's technology softens the brain's stabilizing structures, known as perineuronal nets, to promote neuroplasticity and facilitate the formation of new neural connections.
By restoring brain plasticity to a state reminiscent of early developmental stages, the therapy offers a promising avenue for reshaping detrimental neural structures.
